ABMD - Abiomed share -8.4% despite FQ2 earnings beat

Abiomed ([[ABMD]] -8.1%) FQ2 earnings results as follows:Revenue: $209.8M (+27% Q/Q) (+2% Y/Y)Worldwide Impella® heart pump revenue: $199.7M (+29% Y/Y).Operating income: $61.3M (+2% Y/Y)Gross margin: 81.5% vs. 83.0% last year.Operating cash flow: $77.2MFQ3 revenue outlook: $221M-230M.At the end of the quarter, Abiomed has 929 patents and 835 patents pending due to our continued innovation and expanding our global reach.'Abiomed: A Heartbeat Away From Next Uptick'Previously: Abiomed EPS beats by $0.04, beats on revenue (Oct. 29)

For further details see:

Abiomed share -8.4% despite FQ2 earnings beat